120 related articles for article (PubMed ID: 22581011)
1. Communicating the risks of medicines: time to move forward.
Dal Pan GJ
Med Care; 2012 Jun; 50(6):463-5. PubMed ID: 22581011
[No Abstract] [Full Text] [Related]
2. Toward improved adverse event/suspected adverse drug reaction reporting.
Gross R; Strom BL
Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):89-91. PubMed ID: 12642971
[No Abstract] [Full Text] [Related]
3. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
[No Abstract] [Full Text] [Related]
4. The Vioxx debacle revisited.
Good CB; Kelley CL
Am J Med; 2005 Sep; 118(9):1055-6; author reply 1056-7. PubMed ID: 16164902
[No Abstract] [Full Text] [Related]
5. Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval.
Borer JS; Pouleur H; Abadie E; Follath F; Wittes J; Pfeffer MA; Pitt B; Zannad F
Eur Heart J; 2007 Aug; 28(15):1904-9. PubMed ID: 17615083
[TBL] [Abstract][Full Text] [Related]
6. Striking the right balance.
Nat Rev Drug Discov; 2006 Nov; 5(11):879. PubMed ID: 17117516
[No Abstract] [Full Text] [Related]
7. Going off-label without venturing off-course: evidence and ethical off-label prescribing.
Largent EA; Miller FG; Pearson SD
Arch Intern Med; 2009 Oct; 169(19):1745-7. PubMed ID: 19858430
[No Abstract] [Full Text] [Related]
8. Direct-to-consumer advertising of prescription drugs: balancing benefits and risks, and a way forward.
Kravitz RL; Bell RA
Clin Pharmacol Ther; 2007 Oct; 82(4):360-2. PubMed ID: 17851573
[No Abstract] [Full Text] [Related]
9. Regulatory innovation in postmarketing risk assessment and management.
Staffa JA; Dal Pan GJ
Clin Pharmacol Ther; 2012 Mar; 91(3):555-7. PubMed ID: 22297386
[TBL] [Abstract][Full Text] [Related]
10. Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results.
Falit BP
Seton Hall Law Rev; 2007; 37(4):969-1049. PubMed ID: 18363220
[No Abstract] [Full Text] [Related]
11. Safety in numbers--monitoring risk in approved drugs.
Okie S
N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
[No Abstract] [Full Text] [Related]
12. The drug safety review process.
Somberg J
Am J Ther; 2007; 14(2):119. PubMed ID: 17414577
[No Abstract] [Full Text] [Related]
13. Indication creep: physician beware.
Hébert PC; Stanbrook M
CMAJ; 2007 Sep; 177(7):697, 699. PubMed ID: 17823137
[No Abstract] [Full Text] [Related]
14. Medication risk must be balanced with benefit, not fear.
Jones KW
Ann Pharmacother; 2010 Apr; 44(4):737-9. PubMed ID: 20332340
[TBL] [Abstract][Full Text] [Related]
15. Contributing to drug safety.
Johnson JM
Am J Hosp Pharm; 1990 Jun; 47(6):1280. PubMed ID: 2368721
[No Abstract] [Full Text] [Related]
16. Thinking outside the (black) box: a new research agenda.
Seligman PJ
Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):387-9. PubMed ID: 16739245
[No Abstract] [Full Text] [Related]
17. Communicating the risks and benefits of medicines.
Schmid EF; Smith DA; Ryder SW
Drug Discov Today; 2007 May; 12(9-10):355-64. PubMed ID: 17467571
[TBL] [Abstract][Full Text] [Related]
18. Reporting adverse effects: a practice to be encouraged.
Prescrire Int; 2013 Mar; 22(136):83. PubMed ID: 23593701
[No Abstract] [Full Text] [Related]
19. Post-market drug safety evidence sources: an analysis of FDA drug safety communications.
Ishiguro C; Hall M; Neyarapally GA; Dal Pan G
Pharmacoepidemiol Drug Saf; 2012 Oct; 21(10):1134-6. PubMed ID: 23033257
[No Abstract] [Full Text] [Related]
20. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
Murphy S; Roberts R
J Allergy Clin Immunol; 2006 Jan; 117(1):34-9. PubMed ID: 16387581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
